TickerFacts.

Organogenesis Holdings Inc. (ORGO): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

$59.97M
Year ended 2025-12-31
-$19.93M
Trailing 12 months to 2026-06-30
+28.7%
3-year compound annual growth
2022-12-31: $28.15M2023-12-31: $22.97M2024-12-31: $12.34M2025-12-31: $59.97M$59.97M
2022-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31$59.97M+386.0%2026-02-26, From 2025-01-01
2024-12-31$12.34M-46.3%2026-02-26, From 2024-01-01
2023-12-31$22.97M-18.4%2026-02-26, From 2023-01-01
2022-12-31$28.15Mn/a2025-02-27, From 2022-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Organogenesis Holdings Inc. (ORGO)2025-12-31$59.97M+386.0%
HUTCHMED (China) Ltd (HCM)2025-12-31-$25.85Mn/m
Opko Health, Inc. (OPK)2025-12-31-$25.78Mn/m
Mirum Pharmaceuticals, Inc. (MIRM)2025-12-31$2.11Mn/m
TG Therapeutics, Inc. (TGTX)2025-12-31$123.38M+193.8%
BridgeBio Pharma, Inc. (BBIO)2025-12-31-$517.98Mn/m
Travere Therapeutics, Inc. (TVTX)2025-12-31-$2.08Mn/m
Nature's Sunshine Products Inc (NATR)2025-12-31$38.59M+12.5%
Ultragenyx Pharmaceutical Inc. (RARE)2025-12-31-$500.00Mn/m

Compare ORGO, HCM, OPK, MIRM side by side · Screen every company in Pharmaceutical Preparations ↗